|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
OCTOBER 20, 2003
How Immune Response Targets AIDS  I mmune Response (IMNR
), co-founded in the late 1980s by Dr. Jonas Salk, developer of the polio vaccine, has talked to two drugmakers as possible partners for its new drug Remune. This is an immune-based therapy for HIV patients who haven't yet taken antiretroviral drugs (the so-called cocktail). Now in Phase 2 clinical trials in Spain and having just started tests in Italy, Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. CEO John Bonfiglio says Remune boosts the immune system to attack HIV and stimulates HIV-specific immune responses. Confirming his talks with possible partners, Bonfiglio says a partnership would speed tests. Robert Wasserman of Dawson James Securities says a marketing partner would boost the stock and enhance approval of Remune in three to five years. He rates the stock, at 2.45 a share, a buy -- with a 12-month price target of 8. Alan Jacobs of Capital Growth Equity Fund, which owns shares, reports that earlier trials were "promising."
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2003, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Policy |
Printer-Friendly Version
